206 related articles for article (PubMed ID: 27589335)
1. Synthesis and biological evaluation of novel dasatinib analogues as potent DDR1 and DDR2 kinase inhibitors.
Liu L; Hussain M; Luo J; Duan A; Chen C; Tu Z; Zhang J
Chem Biol Drug Des; 2017 Mar; 89(3):420-427. PubMed ID: 27589335
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 4-amino-1H-pyrazolo[3,4-d]pyrimidin derivatives as novel discoidin domain receptor 1 (DDR1) inhibitors.
Dong R; Zhou X; Wang M; Li W; Zhang JY; Zheng X; Tang KX; Sun LP
Bioorg Med Chem; 2021 Jan; 29():115876. PubMed ID: 33246255
[TBL] [Abstract][Full Text] [Related]
3. The Journey of DDR1 and DDR2 Kinase Inhibitors as Rising Stars in the Fight Against Cancer.
Elkamhawy A; Lu Q; Nada H; Woo J; Quan G; Lee K
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207360
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.
Day E; Waters B; Spiegel K; Alnadaf T; Manley PW; Buchdunger E; Walker C; Jarai G
Eur J Pharmacol; 2008 Dec; 599(1-3):44-53. PubMed ID: 18938156
[TBL] [Abstract][Full Text] [Related]
5. DDR1 and DDR2 physical interaction leads to signaling interconnection but with possible distinct functions.
Croissant C; Tuariihionoa A; Bacou M; Souleyreau W; Sala M; Henriet E; Bikfalvi A; Saltel F; Auguste P
Cell Adh Migr; 2018; 12(4):324-334. PubMed ID: 29616590
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: cell line-based assay, kinase panel, molecular docking, and toxicity studies.
Elkamhawy A; Park JE; Cho NC; Sim T; Pae AN; Roh EJ
J Enzyme Inhib Med Chem; 2016; 31(1):158-66. PubMed ID: 25807298
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel (E)-1-methyl-9-(3-methylbenzylidene)-6,7,8,9-tetrahydropyrazolo[3,4-d]pyrido[1,2-a]pyrimidin-4(1H)-one as DDR2 kinase inhibitor: Synthesis, molecular docking, and anticancer properties.
Ruzi Z; Bozorov K; Nie L; Zhao J; Akber Aisa H
Bioorg Chem; 2023 Jun; 135():106506. PubMed ID: 37030105
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2- a]pyrazin-3-ylethynyl)-4-isopropyl- N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2.
Wang Z; Zhang Y; Pinkas DM; Fox AE; Luo J; Huang H; Cui S; Xiang Q; Xu T; Xun Q; Zhu D; Tu Z; Ren X; Brekken RA; Bullock AN; Liang G; Ding K; Lu X
J Med Chem; 2018 Sep; 61(17):7977-7990. PubMed ID: 30075624
[TBL] [Abstract][Full Text] [Related]
9. Discovery of
Liu L; Zhao L; Yang L; Chai M; Liu Z; Ma N; Wang Y; Wu Q; Guo J; Zhou F; Huang W; Ren X; Wang J; Ding M; Wang Z; Ding K
J Med Chem; 2024 May; 67(10):8043-8059. PubMed ID: 38730324
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of DDR1 Inhibitors with a Desired Pharmacophore Using Deep Generative Models.
Yoshimori A; Asawa Y; Kawasaki E; Tasaka T; Matsuda S; Sekikawa T; Tanabe S; Neya M; Natsugari H; Kanai C
ChemMedChem; 2021 Mar; 16(6):955-958. PubMed ID: 33289306
[TBL] [Abstract][Full Text] [Related]
11. What Makes a Kinase Promiscuous for Inhibitors?
Hanson SM; Georghiou G; Thakur MK; Miller WT; Rest JS; Chodera JD; Seeliger MA
Cell Chem Biol; 2019 Mar; 26(3):390-399.e5. PubMed ID: 30612951
[TBL] [Abstract][Full Text] [Related]
12. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.
Canning P; Tan L; Chu K; Lee SW; Gray NS; Bullock AN
J Mol Biol; 2014 Jun; 426(13):2457-70. PubMed ID: 24768818
[TBL] [Abstract][Full Text] [Related]
13. Clustering, Spatial Distribution, and Phosphorylation of Discoidin Domain Receptors 1 and 2 in Response to Soluble Collagen I.
Yeung DA; Shanker N; Sohail A; Weiss BA; Wang C; Wellmerling J; Das S; Ganju RK; Miller JLC; Herr AB; Fridman R; Agarwal G
J Mol Biol; 2019 Jan; 431(2):368-390. PubMed ID: 30458172
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of discoidin domain receptors by imatinib prevented pancreatic fibrosis demonstrated in experimental chronic pancreatitis model.
Bansod S; Saifi MA; Godugu C
Sci Rep; 2021 Jun; 11(1):12894. PubMed ID: 34145346
[TBL] [Abstract][Full Text] [Related]
16. DDR1 and DDR2 in skin.
Cario M
Cell Adh Migr; 2018; 12(4):386-393. PubMed ID: 29952722
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, anticancer, and docking studies of salicyl-hydrazone analogues: A novel series of small potent tropomyosin receptor kinase A inhibitors.
Alam MS; Choi SU; Lee DU
Bioorg Med Chem; 2017 Jan; 25(1):389-396. PubMed ID: 27856237
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Pyrazolo[3,4-
Tan X; Li C; Yang R; Zhao S; Li F; Li X; Chen L; Wan X; Liu X; Yang T; Tong X; Xu T; Cui R; Jiang H; Zhang S; Liu H; Zheng M
J Med Chem; 2022 Jan; 65(1):103-119. PubMed ID: 34821145
[TBL] [Abstract][Full Text] [Related]
19. Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities.
Abouzid KAM; Al-Ansary GH; El-Naggar AM
Eur J Med Chem; 2017 Jul; 134():357-365. PubMed ID: 28431341
[TBL] [Abstract][Full Text] [Related]
20. Part-1: Design, synthesis and biological evaluation of novel bromo-pyrimidine analogs as tyrosine kinase inhibitors.
Munikrishnappa CS; Puranik SB; Kumar GV; Prasad YR
Eur J Med Chem; 2016 Aug; 119():70-82. PubMed ID: 27155464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
